Research ArticleClinical Studies

Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma

YASUKATA OHASHI, MEGUMI YATABE, DAISUKE NIIJIMA, KENTARO TANI, CHIAKI OGAWA, YUTAKA YACHI, TOSHIYA KAGOO, SAIGEN BOKU, HIRONORI UENO, TAKAHIRO YANO, KOJI HIGAI and AKIHIRO YOKOYAMA
In Vivo September 2020, 34 (5) 2821-2828; DOI: https://doi.org/10.21873/invivo.12108

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Swimmer plot presenting ixazomib dosing history up to the cut-off date in dose-escalation (A) and standard-dose (B) groups. Individual patients are represented throughout the different cycles by a horizontal series of bars. There are up to three doses of ixazomib in one cycle, and each dose is represented by a rectangle. †Censored case.

  • Figure 2.
    Figure 2.

    Kaplan-Meier plots of time to treatment discontinuation (TTD) in the dose-escalation (DE) and standard-dose (SD) groups. Censored patients are marked on the curves with a cross. CI: Confidence interval; NA: Not applicable.

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
YASUKATA OHASHI, MEGUMI YATABE, DAISUKE NIIJIMA, KENTARO TANI, CHIAKI OGAWA, YUTAKA YACHI, TOSHIYA KAGOO, SAIGEN BOKU, HIRONORI UENO, TAKAHIRO YANO, KOJI HIGAI, AKIHIRO YOKOYAMA
In Vivo Sep 2020, 34 (5) 2821-2828; DOI: 10.21873/invivo.12108
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords